LC-Fatty Acid Oxidation Disorders: Recent Updates on the REN001 Study

Print Friendly, PDF & Email

There was much discussion about current research in FAODs at the 2022 International Metabolic conference. Reneo Pharmaceuticals recently released positive results from the REN001 Phase1b LC-FAOD Study. 

Dr. Alex Dorenbaum, Chief Medical Officer at Reneo Pharmaceuticals will provide background about the Reneo LC-FAOD clinical study and answer questions.

Date: 08/18/2022
Listen Now: Click Here

Related Articles